Cesca Therapeutics partnership positive, says H.C. Wainwright After Cesca (KOOL) announced an expanded collaboration with pan Asia-Pacific hospital owner Fortis Healthcare, H.C. Wainwright believes the announcement is "excellent news." The firm thinks the deal gives Cesca a stronger foothold in Asia and could enable its new cell therapy treatments to be approved more quickly. The firm views the stock as undervalued and keeps a $5 price target and Buy rating on the shares.
Cesca Therapeutics to delay filing Form 10-Q The registrant is unable to file its Quarterly Report on Form 10-Q for the quarter ended March 31, within the prescribed time period. As reported in the company’s Form 8-K dated May 12, the former independent registered public accounting firm resigned. The company needs more time to engage a successor independent registered public accounting firm and allow them time to review the management prepared Form 10-Q. No assurance can be given that the company will be able to file its quarterly report within the additional time prescribed by Rule 12b-25.